Exposing the misleading claims of the American Kratom Association
— and the evidence they ignore.
In legislative hearings, media appearances, and public materials, the American Kratom Association (AKA) repeats a set of carefully crafted claims. Below, we examine their most common statements alongside the evidence they omit.
Our theme throughout: The industry exploits scientific uncertainty to argue for safety, when in fact uncertainty demands caution and regulation.
Claim 1: “Kratom appears to be well tolerated in humans at all dose levels based on the FDA Single Ascending Dose study.”
Rebuttal: A small single-dose tolerability study with about 40 participants does not establish safety. It only evaluates short-term acute effects under controlled conditions, not long-term use, addiction potential, drug interactions, or risks from retail products.
Claim 2: “Only two subjects experienced nausea at extremely high doses.”
Rebuttal: That finding simply reflects the limited scope of the study, not the absence of harm. Rare but serious adverse effects cannot be detected in a study with only a few dozen participants.
Claim 3: “The FDA tried to schedule kratom three times and failed.”
Rebuttal: Regulatory caution is not proof of safety. Agencies often delay scheduling while evidence develops. The FDA still warns against kratom use and has rejected attempts to market it as a dietary supplement due to safety concerns.
Claim 4: “Most kratom deaths involve other drugs or adulterants.”
Rebuttal: Polydrug use is common in toxicology cases. The presence of other substances does not mean kratom is harmless—it highlights the danger of selling a psychoactive product without quality control or interaction warnings.
Claim 5: “Millions of Americans use kratom safely.”
Rebuttal: This estimate comes largely from industry surveys and advocacy sources, not controlled epidemiological studies. Popularity is not evidence of safety—tobacco and opioids were once widely used before their risks were fully recognized.
Claim 6: “Kratom is not an opioid.”
Rebuttal: While not chemically identical to morphine, kratom’s primary alkaloids bind to the same mu-opioid receptors in the brain, producing opioid-like effects including analgesia and potential dependence.
Claim 7: “Kratom has no significant respiratory depression like opioids.”
Rebuttal: Absence of severe respiratory depression in animal models does not eliminate other risks such as addiction, withdrawal, cardiovascular effects, or toxicity when combined with other drugs.
Claim 8: “Kratom is safer than opioids and helps people quit them.”
Rebuttal: Potential harm-reduction effects are still under investigation and do not justify unregulated retail sales. Medications used to treat opioid addiction undergo rigorous clinical trials and physician oversight—kratom products do not.
Claim 9: “Kratom can legally be marketed as a food or dietary product.”
Rebuttal: The FDA has rejected kratom as a dietary ingredient because there is insufficient evidence of safety, and it has warned against using kratom products for medical treatment.
Claim 10: “Kratom overdose risk is extremely low compared with opioids.”
Rebuttal: The comparison is misleading. Opioids are highly lethal drugs used medically. The relevant question is whether kratom—a psychoactive substance sold without dosing standards or manufacturing controls—should be widely available in retail stores.
✅ The strongest theme across their materials is argument from uncertainty.
They repeatedly say: “The science isn’t settled.” But then conclude: “Therefore kratom is safe.”
“Scientific uncertainty is not evidence of safety. It is a reason for caution and regulation.”